FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2556113896> ?p ?o ?g. }

• W2556113896 abstract "Abstract Abstract 3557 Background – Activating mutations of the transmembrane receptor tyrosine kinase, FLT3, occur in approximately 30% of patient with acute myeloid leukemia (AML) and predict for a shorter relapse-free and overall survival. There is limited data on loss or persistence of the mutated clones at the time of complete response (CR) and their recurrence at the time of relapse. Objectives and Methods – To evaluate patterns of loss and recurrence of FLT3 mutated clones in relation to response and relapse in patients with FLT3 mutated AML treated with idarubicin and cytarabine (IA) with or without sorafenib (S), vorinostat (V), or tipifarnib (T). Bone marrow samples at diagnosis, CR and relapse were examined for the presence of FLT3 mutated clones using reverse transcription polymerase chain reaction. Results – Among 361 patients with AML treated from October 2004 to March 2010 on one of the 4 induction regimens of IA, IAS, IAV, and IAT, 321 had presentation bone marrow samples tested and 72 had FLT3 mutations (including 50 with ITD and 16 D835 with 6 having both). The median age for the entire group was 53 years (range, 17–73) and for the FLT3 mutated patients 52 years (range, 17 to 73). Cytogenetics at diagnosis in FLT3 mutated patients included normal karyotype in 48 (67%) patients, chromosome 5 and 7 abnormalities in 4(6%), trisomy 8 in 4(6%), 11q abnormalities in 2 (3%), insufficient metaphases in 3(4%), and miscellaneous in 11(16%). 271 (75%) patients overall, and 64 (89%) patients with mutated FLT3 achieved CR. Among the 56 patients with presentation FLT3-ITD, 51 achieved CR. Among 13 patients with available samples at CR, none had FLT3-ITD; 8 of these patients relapsed and 5 had FLT3-ITD positive clones at relapse (2 negative and 1 not done); Among the 38 patients with no samples at CR, 17 relapsed, 8 with a FLT3-ITD clone (1 negative and 8 not done). Among the 201 patients without FLT3-ITD at diagnosis, who achieved CR, 8 patients acquired a clone with FLT3-ITD at relapse. Conclusions – FLT3-ITD mutant clones are unstable at follow-up. Relapse may occur in their absence and they may occur for the first time at relapse. Therefore, FLT3-ITD cannot be used reliably for minimal residual leukemia monitoring. Disclosures: Ravandi: Bayer Onyx: Honoraria, Research Funding." @default.
• W2556113896 created "2016-11-30" @default.
• W2556113896 creator A5000750846 @default.
• W2556113896 creator A5006104041 @default.
• W2556113896 creator A5015101485 @default.
• W2556113896 creator A5020340537 @default.
• W2556113896 creator A5028845635 @default.
• W2556113896 creator A5036349678 @default.
• W2556113896 creator A5046097970 @default.
• W2556113896 creator A5055045706 @default.
• W2556113896 creator A5061026876 @default.
• W2556113896 creator A5073079562 @default.
• W2556113896 creator A5086233229 @default.
• W2556113896 creator A5090435894 @default.
• W2556113896 date "2011-11-18" @default.
• W2556113896 modified "2023-10-15" @default.
• W2556113896 title "Activating Mutations of the FMS-Like Tyrosine Kinase-3 (FLT3) At Complete Response and Relapse in Patients with Acute Myeloid Leukemia," @default.
• W2556113896 doi "https://doi.org/10.1182/blood.v118.21.3557.3557" @default.
• W2556113896 hasPublicationYear "2011" @default.
• W2556113896 type Work @default.
• W2556113896 sameAs 2556113896 @default.
• W2556113896 citedByCount "0" @default.
• W2556113896 crossrefType "journal-article" @default.
• W2556113896 hasAuthorship W2556113896A5000750846 @default.
• W2556113896 hasAuthorship W2556113896A5006104041 @default.
• W2556113896 hasAuthorship W2556113896A5015101485 @default.
• W2556113896 hasAuthorship W2556113896A5020340537 @default.
• W2556113896 hasAuthorship W2556113896A5028845635 @default.
• W2556113896 hasAuthorship W2556113896A5036349678 @default.
• W2556113896 hasAuthorship W2556113896A5046097970 @default.
• W2556113896 hasAuthorship W2556113896A5055045706 @default.
• W2556113896 hasAuthorship W2556113896A5061026876 @default.
• W2556113896 hasAuthorship W2556113896A5073079562 @default.
• W2556113896 hasAuthorship W2556113896A5086233229 @default.
• W2556113896 hasAuthorship W2556113896A5090435894 @default.
• W2556113896 hasConcept C104317684 @default.
• W2556113896 hasConcept C126322002 @default.
• W2556113896 hasConcept C143998085 @default.
• W2556113896 hasConcept C174475383 @default.
• W2556113896 hasConcept C203014093 @default.
• W2556113896 hasConcept C2778041864 @default.
• W2556113896 hasConcept C2778461978 @default.
• W2556113896 hasConcept C2778729363 @default.
• W2556113896 hasConcept C2779117419 @default.
• W2556113896 hasConcept C2779282312 @default.
• W2556113896 hasConcept C2780007613 @default.
• W2556113896 hasConcept C2780365373 @default.
• W2556113896 hasConcept C2910954276 @default.
• W2556113896 hasConcept C30481170 @default.
• W2556113896 hasConcept C501734568 @default.
• W2556113896 hasConcept C502942594 @default.
• W2556113896 hasConcept C54355233 @default.
• W2556113896 hasConcept C71924100 @default.
• W2556113896 hasConcept C86803240 @default.
• W2556113896 hasConcept C90924648 @default.
• W2556113896 hasConceptScore W2556113896C104317684 @default.
• W2556113896 hasConceptScore W2556113896C126322002 @default.
• W2556113896 hasConceptScore W2556113896C143998085 @default.
• W2556113896 hasConceptScore W2556113896C174475383 @default.
• W2556113896 hasConceptScore W2556113896C203014093 @default.
• W2556113896 hasConceptScore W2556113896C2778041864 @default.
• W2556113896 hasConceptScore W2556113896C2778461978 @default.
• W2556113896 hasConceptScore W2556113896C2778729363 @default.
• W2556113896 hasConceptScore W2556113896C2779117419 @default.
• W2556113896 hasConceptScore W2556113896C2779282312 @default.
• W2556113896 hasConceptScore W2556113896C2780007613 @default.
• W2556113896 hasConceptScore W2556113896C2780365373 @default.
• W2556113896 hasConceptScore W2556113896C2910954276 @default.
• W2556113896 hasConceptScore W2556113896C30481170 @default.
• W2556113896 hasConceptScore W2556113896C501734568 @default.
• W2556113896 hasConceptScore W2556113896C502942594 @default.
• W2556113896 hasConceptScore W2556113896C54355233 @default.
• W2556113896 hasConceptScore W2556113896C71924100 @default.
• W2556113896 hasConceptScore W2556113896C86803240 @default.
• W2556113896 hasConceptScore W2556113896C90924648 @default.
• W2556113896 hasLocation W25561138961 @default.
• W2556113896 hasOpenAccess W2556113896 @default.
• W2556113896 hasPrimaryLocation W25561138961 @default.
• W2556113896 hasRelatedWork W1504864970 @default.
• W2556113896 hasRelatedWork W177771527 @default.
• W2556113896 hasRelatedWork W2022307983 @default.
• W2556113896 hasRelatedWork W2028988847 @default.
• W2556113896 hasRelatedWork W2047398950 @default.
• W2556113896 hasRelatedWork W2066705583 @default.
• W2556113896 hasRelatedWork W2092520330 @default.
• W2556113896 hasRelatedWork W2093686057 @default.
• W2556113896 hasRelatedWork W2111210736 @default.
• W2556113896 hasRelatedWork W2362763269 @default.
• W2556113896 hasRelatedWork W2382334204 @default.
• W2556113896 hasRelatedWork W2551176543 @default.
• W2556113896 hasRelatedWork W2563384690 @default.
• W2556113896 hasRelatedWork W2567714654 @default.
• W2556113896 hasRelatedWork W2581748155 @default.
• W2556113896 hasRelatedWork W2586926717 @default.
• W2556113896 hasRelatedWork W2901821065 @default.
• W2556113896 hasRelatedWork W3029108770 @default.
• W2556113896 hasRelatedWork W3209941199 @default.
• W2556113896 hasRelatedWork W88998843 @default.
• W2556113896 isParatext "false" @default.
• W2556113896 isRetracted "false" @default.

• next